Evaluation of the time dependent variability of the anti-factor Xa activity of therapeutic nadroparin in critically ill patients: a pharmacokinetic study

Evaluation of the time dependent variability of the anti-factor Xa activity of therapeutic nadroparin in critically ill patients: a pharmacokinetic study - VARIAXA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48502

Enrollment

Registered

2020-02-13

Start date

2020-08-24

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Farmacokinetiek van therapeutisch gedoseerd Nadroparine pharmacokinetics nadroparin

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) Admitted to the Intensive Care with nadroparin in therapeutic dose (1-daily or 2-daily) (2) Age * 18 years

Exclusion criteria

Exclusion criteria: (1) Pregnancy (2) Requiring hemodialysis (HD) or Continuous Veno-Venous Hemofiltration (CVVH) (3) Treated with a DOAC, unfractionated heparin, another LMWH, a GP IIb / IIIa receptor antagonist 96 hours to 0 hours before the first bloodsample is drawn or during bloodsampling. (4) Participation in another study

Design outcomes

Primary

Measure	Time frame
{[Cmax at tmax] minus [minimal measured anti-Xa between T3h to 5h] / [Cmax at tmax] } · 100%	—

Secondary

Measure	Time frame
To evaluate the pharmacokinetics of therapeutic nadroparin in a general intensive care unit population by measuring anti-factor Xa levels.	—

Countries

Netherlands

Outcome results